講師
- 籌備委員會成員
- 國際委員會
- 公司展望說明會
- Entrepreneur Pitch
- Session 1&2 – Global Biotech Development
- Session 3 –Gap Filling of Health Investment for a Brighter Futur
- Session 4 – How to Bring New Drugs to Global Markets?
- Session 5 – Invest for 2024 and Beyond
- Session 6 - BIO Asia–Taiwan 2023 Opening & Award Ceremony
- Session 7 - Sharing Biotech Successes-Taiwan BIO Awardee Showcas
- Session 8 – Crossing Borders, Establishing a Global Biotech Ecos
- Session 9 – New Asian Age
- Session 10 – Clinical Impacts of Precision Health
- Session 11 – Cell and Gene Therapies with Novel Enabling Platfor
- Session 12 – New Modality Development
- Session 13 – Empowering Patient-centric Digital Health
- Session 14 – Robust Manufacturing for Cell and Biologics
- Session 15 – Biodesign for the Future of MedTech
- Satellite Conference
- 2023 Regional Collaboration Forum
- 2023 Focus Symposia
酷氏基因生物科技股份有限公司
Company Info
Name /Guzip Biomarkers Corporation
Address /4F., No. 66, Shengyi 5th Rd., Zhubei City, Hsinchu County 302041, Taiwan (R.O.C.)
Presenter
Name /Polly Lin
Title /CEO
Email /pollylin@guzipbio.com
Telephone /+886-3-578-1168 #30108
Fax /+886-3-578-5099
Mobile /0910390169
Company Type
Biotechnology
About the Company
Guzip Biomarkers Corporation (Guzip), a Taiwan startup established in 2018, is specialized at providing novel DNA methylation epigenetic biomarkers for applications in the clinic. Our company vision is to create a better and healthier day for woman and girls, providing accurate, affordable, and safe medical solutions to women.
Brief Description of main products or services
MPapⓇ test
Our first product, MPapⓇ test, is an innovative molecular diagnostic test that can be used for endometrial cancer.
The MPapⓇ test as an auxiliary test for Endometrial Cancer qualitatively detects the methylation status of BHLHE22 and CDO1 genes with Methylation-Specific qPCR (MSP) technology. The test results provide doctors a reference to evaluate how susceptible a woman with abnormal uterine bleeding (AUB), aged >40 or postmenopausal, is to EC, for the justification of whether an invasive endometrial diagnostic procedure (IVP) or conservative treatment to proceed.
Other product pipeline
Guzip also develops the methylation biomarkers for upper urinary tract urothelial carcinoma (UTUC), and predicting biomarkers for the endometrial receptivity during in vitro fertilization (IVF) process.